Electronic Rebate Claim Validation via 340B Program Matching
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The complexity in claims processing systems within the 340B program makes it difficult for drug manufacturers to discern whether a prescription was sold at the 340B price or outside of the program, leading to potential duplicate discounts when rebates are applied.
Innovation Solution
A system that validates electronic rebate claims using electronic prescription claims and patient encounter data, determining whether a prescription is associated with the 340B program by matching prescription information and generating a discount indicator to prevent duplicate discounts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If rebate claims are processed without validating 340B program status, then rebate processing speed is improved, but duplicate discounts occur leading to financial loss
Solution Approach 1:
The system performs preliminary validation by matching prescription information against 340B program data before processing rebates. This advance check prevents duplicate discounts by identifying 340B prescriptions upfront, allowing the system to reject ineligible rebate claims before financial transactions occur, thus maintaining processing speed while preventing losses.
Solution Approach 2:
The system implements a feedback mechanism where validation results from the prescription-340B data matching are fed back into the rebate processing decision. This closed-loop control ensures that only prescriptions confirmed to be outside the 340B program receive rebates, eliminating duplicate discounts while maintaining efficient processing through automated decision rules.
2Measurement precision
If prescription information is matched against 340B program data, then accuracy in preventing duplicate discounts is improved, but system complexity increases
Solution Approach 1:
The validation system is designed to perform multiple functions: matching prescription information against 340B data, determining program status, and making rebate eligibility decisions. By consolidating these functions into a single multi-functional module, the system achieves high accuracy in identifying 340B prescriptions while minimizing the complexity increase that would result from multiple separate systems.
Solution Approach 2:
The system introduces an intermediary validation layer between prescription processing and rebate payment. This intermediary component handles the complex matching and determination logic, isolating the complexity from both the prescription intake system and the rebate payment system. The intermediary translates complex validation requirements into simple pass/fail decisions for the surrounding systems.
3Reliability
If comprehensive validation is performed on all rebate claims, then prevention of duplicate discounts is improved, but processing time increases
Solution Approach 1:
The system performs validation selectively rather than universally. It applies comprehensive 340B matching only to prescriptions where there is uncertainty about program status, while quickly approving clearly eligible prescriptions. This partial action approach maintains high reliability in preventing duplicate discounts while minimizing processing time for the majority of straightforward cases.
Solution Approach 2:
The validation process applies different levels of scrutiny to different prescriptions based on their characteristics. Prescriptions with clear identifiers are processed through a fast track with minimal validation, while those with ambiguous or missing information receive comprehensive 340B data matching. This localized quality approach ensures reliable prevention of duplicate discounts only where necessary, reducing overall processing time.
Data Source
AI summary
A method, apparatus and computer program product are provided for providing rebate claim validation. A drug manufacturer or associated computer may receive rebate claims from pharmacy benefit managers (PBMs). The manufacturer should not be obligated to pay the rebate if the associated prescription drug was initially sold by the manufacturer under a discount program such as 340B. However, manufacturers may not be able to discern which rebate claims are associated with a discount program. A service provider utilizes adjudicated prescription claims from a contract pharmacy, and encounter data from a covered entity to validate the rebate claims and indicate to the manufacturer whether a rebate claim is associated with a discount program such as 340B.